To determine the difference in change in apoptosis between diagnosis and surgery as a function of ruxolitinib treatment versus placebo, among participants with high-risk or premalignant breast conditions.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
North Carolina (Statewide)
Kristalyn Gallagher
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Breast)
19-0116